The merger creates a highly complementary and integrated leader in the CDMO industry, with a combined workforce of over 400 people and a commitment to innovation and quality.
Founders
Riccardo Braglia, Waldo Mossi, Christian Suà
Company Description
HAS develops and manufactures active pharmaceutical ingredients, cGMP advanced intermediates, and high-potency APIs.